General

Guideline Title

Clinical policy: critical issues in the initial evaluation and management of patients presenting to the emergency department in early pregnancy.

Bibliographic Source(s)


Guideline Status

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

Recommendations

Major Recommendations

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.

Definitions for the strength of evidence (Class I-III) and strength of recommendations (Level A-C) are repeated at the end of the Major Recommendations field.

1. Should the emergency physician obtain a pelvic ultrasound in a clinically stable pregnant patient who presents to the emergency department (ED) with abdominal pain and/or vaginal bleeding and a β-human chorionic gonadotropin (β-hCG) level below a discriminatory threshold?

   Patient Management Recommendations

   Level A recommendations. None specified.

   Level B recommendations. None specified.

   Level C recommendations. Perform or obtain a pelvic ultrasound for symptomatic pregnant patients with a β-hCG level below any discriminatory threshold.

2. In patients who have an indeterminate transvaginal ultrasound, what is the diagnostic utility of β-hCG for predicting possible ectopic pregnancy?

   Patient Management Recommendations

   Level A recommendations. None specified.
Level B recommendations. Do not use the β-hCG value to exclude the diagnosis of ectopic pregnancy in patients who have an indeterminate ultrasound.

Level C recommendations. Obtain specialty consultation or arrange close outpatient follow-up for all patients with an indeterminate pelvic ultrasound.

3. In patients receiving methotrexate for confirmed or suspected ectopic pregnancy, what are the implications for ED management?

Patient Management Recommendations

Level A recommendations. None specified.

Level B recommendations. (1) Arrange outpatient follow-up for patients who receive methotrexate therapy in the ED for a confirmed or suspected ectopic pregnancy. (2) Strongly consider ruptured ectopic pregnancy in the differential diagnosis of patients who have received methotrexate and present with concerning signs or symptoms.

Level C recommendations. None specified.

Recommendations from the 2003 Clinical Policy

Is the administration of anti-D immunoglobulin indicated among Rhesus (Rh)-negative women during the first trimester of pregnancy with threatened abortion, complete abortion, ectopic pregnancy, or minor abdominal trauma?

Level A recommendations. None specified.

Level B recommendations. Administer 50 µg of anti-D immunoglobulin to Rh-negative women in all cases of documented first trimester loss of established pregnancy.

Level C recommendations. Consider administration of anti-D immunoglobulin in cases of minor trauma in Rh-negative patients.

Note: The patient management recommendations for this question remain unchanged and are not discussed in further detail in the policy update.

Definitions:

Strength of Evidence

Literature Classification Schema*

<table>
<thead>
<tr>
<th>Design/Class</th>
<th>Therapy†</th>
<th>Diagnosis‡</th>
<th>Prognosis§</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Randomized, controlled trial or meta-analysis of randomized trials</td>
<td>Prospective cohort using a criterion standard or meta-analysis of prospective studies</td>
<td>Population prospective cohort or meta-analysis of prospective studies</td>
</tr>
<tr>
<td>2</td>
<td>Nonrandomized trial</td>
<td>Retrospective observational</td>
<td>Retrospective cohort Case control</td>
</tr>
<tr>
<td>3</td>
<td>Case series Case report Other (e.g., consensus, review)</td>
<td>Case series Case report Other (e.g., consensus, review)</td>
<td>Case series Case report Other (e.g., consensus, review)</td>
</tr>
</tbody>
</table>

*Some designs (e.g., surveys) will not fit this schema and should be assessed individually.

†Objective is to measure therapeutic efficacy comparing interventions.

‡Objective is to determine the sensitivity and specificity of diagnostic tests.

§Objective is to predict outcome including mortality and morbidity.

Approach to Downgrading Strength of Evidence*

<table>
<thead>
<tr>
<th>Design/Class</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Downgrading</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>3</td>
</tr>
</tbody>
</table>
**Clinical Algorithm(s)**

None provided

**Scope**

**Disease/Condition(s)**

- Abdominal pain and/or vaginal bleeding in the first trimester of pregnancy (also referred to as "early pregnancy")
- Ectopic pregnancy

**Guideline Category**

Diagnosis
Evaluation
Management
Treatment

**Clinical Specialty**

Emergency Medicine
Family Practice
Internal Medicine
Obstetrics and Gynecology
Intended Users
Physicians

Guideline Objective(s)
- To update the 2003 Clinical policy: critical Issues in the initial evaluation and management of patients presenting to the emergency department in early pregnancy
- To derive evidence-based recommendations to help clinicians answer the following critical questions:
  - Should the emergency physician obtain a pelvic ultrasound in a clinically stable pregnant patient who presents to the emergency department (ED) with abdominal pain and/or vaginal bleeding and a beta human chorionic gonadotropin (β-hCG) level below a discriminatory threshold?
  - In patients who have an indeterminate transvaginal ultrasound, what is the diagnostic utility of β-hCG for predicting possible ectopic pregnancy?
  - In patients receiving methotrexate for confirmed or suspected ectopic pregnancy, what are the implications for ED management?

Target Population
Patients presenting to the emergency department in early pregnancy

Interventions and Practices Considered

Diagnosis/Evaluation
1. Assessment of serum β-human chorionic gonadotropin (hCG) levels
2. Pelvic ultrasound

Management/Treatment
1. Specialty consultation or close outpatient follow-up for patients with an indeterminate pelvic ultrasound
2. Methotrexate
3. Anti-D immunoglobulin
4. Outpatient follow-up for patients who receive methotrexate in the emergency department

Major Outcomes Considered
- Incidence of ectopic pregnancy
- Sensitivity and specificity of diagnostic tests
- Incidence of treatment failure
- Need for surgery for ruptured ectopic pregnancy
- Adverse effects of treatment

Methodology

Methods Used to Collect/Select the Evidence

Hand-searches of Published Literature (Primary Sources)
Hand-searches of Published Literature (Secondary Sources)
Searches of Electronic Databases
Description of Methods Used to Collect/Select the Evidence

This clinical policy was created after careful review and critical analysis of the medical literature. Multiple searches of MEDLINE and Google Scholar were performed. All searches were limited to English-language sources and human studies. Specific key words/phrases and years used in the searches are identified under each critical question in the original guideline document. In addition, relevant articles from the bibliographies of included studies and more recent articles identified by committee members and reviewers were included.

Number of Source Documents

Not stated

Methods Used to Assess the Quality and Strength of the Evidence

Weighting According to a Rating Scheme (Scheme Given)

Rating Scheme for the Strength of the Evidence

Strength of Evidence

*Literature Classification Schema*

<table>
<thead>
<tr>
<th>Design/Class</th>
<th>Therapy†</th>
<th>Diagnosis‡</th>
<th>Prognosis§</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Randomized, controlled trial or meta-analysis of randomized trials</td>
<td>Prospective cohort using a criterion standard or meta-analysis of prospective studies</td>
<td>Population prospective cohort or meta-analysis of prospective studies</td>
</tr>
<tr>
<td>2</td>
<td>Nonrandomized trial</td>
<td>Retrospective observational</td>
<td>Retrospective cohort Case control</td>
</tr>
<tr>
<td>3</td>
<td>Case series Case report Other (e.g., consensus, review)</td>
<td>Case series Case report Other (e.g., consensus, review)</td>
<td>Case series Case report Other (e.g., consensus, review)</td>
</tr>
</tbody>
</table>

*Some designs (e.g., surveys) will not fit this schema and should be assessed individually.

†Objective is to measure therapeutic efficacy comparing interventions.

‡Objective is to determine the sensitivity and specificity of diagnostic tests.

§Objective is to predict outcome including mortality and morbidity.

Approach to Downgrading Strength of Evidence*

<table>
<thead>
<tr>
<th>Design/Class</th>
<th>Downgrading</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None</td>
</tr>
<tr>
<td>1 level</td>
<td>I</td>
</tr>
<tr>
<td>2 levels</td>
<td>III</td>
</tr>
<tr>
<td>Fatally flawed</td>
<td>X</td>
</tr>
</tbody>
</table>

*See the "Description of Methods Used to Analyze the Evidence" field for more information.
Methods Used to Analyze the Evidence

Systematic Review with Evidence Tables

Description of the Methods Used to Analyze the Evidence

All articles used in the formulation of this clinical policy were graded by at least 2 subcommittee members for strength of evidence. The articles were classified by the subcommittee members into 3 classes of evidence on the basis of the design of the study, with design 1 representing the strongest design and design 3 representing the weakest design for therapeutic, diagnostic, and prognostic clinical reports, respectively (see the "Rating Scheme for the Strength of the Evidence" field). Articles were then graded on dimensions related to the study's methodological features, including but not necessarily limited to randomization processes, blinding, allocation concealment, methods of data collection, outcome measures and their assessment, selection and misclassification biases, external validity, generalizability, and sample size. Articles received a final grade (Class I, II, III) on the basis of a predetermined formula, taking into account the design and study quality (see the "Rating Scheme for the Strength of the Evidence" field). Articles identified with fatal flaws or that were not relevant to the critical question received an "X" grade and were not used in formulating recommendations for this policy. Grading was done with respect to the specific critical questions; thus, the level of evidence for any one study may vary according to the question. As such, it was possible for a single article to receive different levels of grading as different critical questions were answered from the same study. Question-specific level of evidence grading may be found in the Evidentiary Table at the end of the original guideline document.

Methods Used to Formulate the Recommendations

Expert Consensus

Description of Methods Used to Formulate the Recommendations

This policy is a product of the American College of Emergency Physicians (ACEP) clinical policy development process, including expert review, and is based on the existing literature; where literature was not available, consensus of emergency physicians was used.

Rating Scheme for the Strength of the Recommendations

Clinical findings and strength of recommendations regarding patient management were made according to the following criteria:

Strength of Recommendations

Level A recommendations. Generally accepted principles for patient management that reflect a high degree of clinical certainty (i.e., based on strength of evidence Class I or overwhelming evidence from strength of evidence Class II studies that directly address all of the issues).

Level B recommendations. Recommendations for patient management that may identify a particular strategy or range of management strategies that reflect moderate clinical certainty (i.e., based on strength of evidence Class II studies that directly address the issue, decision analysis that directly addresses the issue, or strong consensus of strength of evidence Class III studies).

Level C recommendations. Other strategies for patient management that are based on Class III studies, or in the absence of any adequate published literature, based on panel consensus.

There are certain circumstances in which the recommendations stemming from a body of evidence should not be rated as highly as the individual studies on which they are based. Factors such as heterogeneity of results, uncertainty about effect magnitude and consequences, and publication bias, among others, might lead to such a downgrading of recommendations.

Cost Analysis

A formal cost analysis was not performed and published cost analyses were not reviewed.
Method of Guideline Validation

External Peer Review

Internal Peer Review

Description of Method of Guideline Validation

Expert review comments were received from emergency physicians, members of the American College of Emergency Physicians (ACEP) Emergency Ultrasound Section, and individual members of the American College of Obstetricians and Gynecologists. Their responses were used to further refine and enhance this policy; however, their responses do not imply endorsement of this clinical policy.

This clinical policy was approved by the ACEP Board of Directors, April 10, 2012.

This guideline is supported by the Emergency Nurses Association, June 21, 2012.

Evidence Supporting the Recommendations

Type of Evidence Supporting the Recommendations

The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).

Benefits/Harms of Implementing the Guideline Recommendations

Potential Benefits

Appropriate evaluation, diagnosis, and management of selected critical issues in patients in early pregnancy

Potential Harms

- Treatment failure, with rupture of the ectopic pregnancy, is one of the most serious complications of methotrexate therapy.
- Other side effects of methotrexate

Contraindications

Methotrexate therapy is contraindicated in patients with alcoholism, immunodeficiency, peptic ulcer, or active disease of the lungs, liver, kidneys, or hematopoietic system and relatively contraindicated in patients with an ectopic gestational sac larger than 3.5 cm or with embryonic cardiac motion observed on ultrasound.

Qualifying Statements

- This policy is not intended to be a complete manual on the evaluation and management of patients with abdominal pain or vaginal bleeding in early pregnancy but rather a focused examination of critical issues that have particular relevance to the current practice of emergency
It is the goal of the Clinical Policies Committee to provide an evidence-based recommendation when the medical literature provides enough quality information to answer a critical question. When the medical literature does not contain enough quality information to answer a critical question, the members of the Clinical Policies Committee believe that it is equally important to alert emergency physicians to this fact.

Recommendations offered in this policy are not intended to represent the only diagnostic and management options that the emergency physician should consider. The American College of Emergency Physicians clearly recognizes the importance of the individual physician’s judgment. Rather, this guideline defines for the physician those strategies for which medical literature exists to provide support for answers to the crucial questions addressed in this policy.

Policy statements and clinical policies are the official policies of the American College of Emergency Physicians (ACEP) and, as such, are not subject to the same peer review process as articles appearing in the print journal. Policy statements and clinical policies of ACEP do not necessarily reflect the policies and beliefs of Annals of Emergency Medicine and its editors.

Implementation of the Guideline

Description of Implementation Strategy

An implementation strategy was not provided.

Institute of Medicine (IOM) National Healthcare Quality Report Categories

IOM Care Need

Getting Better

IOM Domain

Effectiveness

Timeliness

Identifying Information and Availability

Bibliographic Source(s)


Adaptation

Not applicable: The guideline was not adapted from another source.

Date Released

2003 Jan (revised 2012 Sep)
Guideline Developer(s)

American College of Emergency Physicians - Medical Specialty Society

Source(s) of Funding

American College of Emergency Physicians

Guideline Committee

American College of Emergency Physicians (ACEP) Clinical Policies Subcommittee on Early Pregnancy

ACEP Clinical Policies Committee

Composition of Group That Authored the Guideline

*Members of the Clinical Policies Subcommittee on Early Pregnancy*: Sigrid A. Hahn, MD (*Subcommittee Chair*); Eric J. Lavonas, MD; Sharon E. Mace, MD; Anthony M. Napoli, MD; Francis M. Fesmire, MD (*Committee Chair*);

*Members of the Clinical Policies Committee*: Francis M. Fesmire, MD (*Chair 2011-2012*); Douglas Bernstein, MD (*Emergency Medicine Residents Association [EMRA] Representative 2011-2012*); Michael D. Brown, MD, MSc; John H. Burton, MD; Deborah B. Diercks, MD, MSc; Steven A. Godwin, MD; Sigrid A. Hahn, MD; Jason S. Haukoos, MD, MSc (*Methodologist*); J. Stephen Huff, MD; Eric J. Lavonas, MD; Gail Lenahan, EdD, RN, FAEN, FAAN (*Emergency Nurses Association [ENA] Representative 2011-2012*); Sharon E. Mace, MD; Edward Melnick, MD; Devorah J. Nazarian, MD; Susan B. Promes, MD; Richard D. Shah, MD; Scott M. Silvers, MD; Stephen J. Wolf, MD; Stephen V. Cantrill, MD (*Liaison with Quality and Performance Committee*); Robert E. O'Connor, MD, MPH (*Board Liaison 2010-2012*); Rhonda R. Wittson, RHIA, Staff Liaison, Clinical Policies Committee and Subcommittees

Financial Disclosures/Conflicts of Interest

Relevant industry relationships: There were no relevant industry relationships disclosed by the subcommittee members. Relevant industry relationships are those relationships with companies associated with products or services that significantly impact the specific aspect of disease addressed in the critical question.

Guideline Endorser(s)

Emergency Nurses Association - Professional Association

Guideline Status

Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary.

Guideline Availability


ACEP clinical policies are available for mobile applications at the [ACEP Web site](https://www.acep.org).

Availability of Companion Documents

None available
Patient Resources

None available

NGC Status

This NGC summary was completed by ECRI on June 5, 2003. The information was verified by the guideline developer on July 18, 2003. This NGC summary was updated by ECRI Institute on September 28, 2012. The updated information was verified by the guideline developer on October 23, 2012.

Copyright Statement

This NGC summary is based on the original guideline, which is subject to the guideline developer’s copyright restrictions. For more information, please refer to the American College of Emergency Physicians (ACEP) Web site.

Disclaimer

NGC Disclaimer

The National Guideline Clearinghouse® (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.